Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial

Lancet

Volumn 359, Issue 9323, 2002, Pages 2053-2058

  Lederman, Robert J ^a,k   Mendelsohn, Farrell O ^b   Anderson, R David ^c   Saucedo, Jorge F ^d   Tenaglia, Alan N ^e   Hermiller, James B ^f   Hillegass, William B ^g   Rocha Singh, Krishna ^h   Moon, Thomas E ⁱ   Whitehouse, M J ⁱ   Annex, Brian H ^j  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b 318 LHRB   (United States)

^c SARASOTA MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e TULANE UNIVERSITY MEDICAL CENTER   (United States)

^f Nasser   (United States)

^g Heart Group   (United States)

^h Prairie Cardiovascular Consultants Ltd   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j DUKE UNIVERSITY   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; HEPARIN; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS; ANKLE PRESSURE; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; WALKING;

EID: 0037097035     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08937-7     Document Type: Article

References (27)

1. Update on some epidemiologic features of intermittent claudication: The Framingham Study
2. Medical treatment of peripheral arterial disease and claudication
3. Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis
4. Therapeutic angiogenesis in ischemic limbs
5. Basic fibroblast growth factor induces angiogenesis in vitro
6. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
7. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
8. Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial
9. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: Design of the TRAFFIC trial
10. Progressive vs single-stage treadmill tests for evaluation of claudication
11. Management of peripheral arterial disease (PAD)
12. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
13. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
14. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication
15. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
16. What is meant by intention to treat analysis? Survey of published randomised controlled trials
17. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
18. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
19. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
20. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
21. Highlights of the 48th scientific sessions of the American College of Cardiology: VIVA trial
22. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial
23. European multicenter study on propionyl-L-carnitine in intermittent claudication
24. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME investigators
25. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis
26. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication